Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Adicet Bio Inc
UndervaluedConclusion
🧐 Nous ne nous engageons pas à parler des perspectives de cette entreprise. Vous devez très bien comprendre pourquoi ce business devrait être dans le portefeuille.
Similar to Adicet Bio Inc

PHM
Pharma Mar S.A.KDEV
Karolinska Development AB ser. BFAB
Fusion Antibodies PLCIPHA
Innate PharmaCSBR
Champions Oncology IncAdicet Bio Inc
ACETAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts. Address: 131 Dartmouth Street, Boston, MA, United States, 02116
Analytics
Objectif de Cours de WallStreet
6.40 USDRatio C/B
–Rendement du dividende
–Chiffres clés ACET
- Marge Bénéficiaire
- Revenu Total
- Bénéfice Brut
- Revenu Net
Analyse des dividendes ACET
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes ACET
- Ratio de Distribution
- Dividends
- Rendement du dividende
Valorisation des titres ACET
- Prix sur Revenu
- Ratio PE
- Prix sur Valeur Comptable
- Ratio de Liquidité Courante
- Ratio d'Endettement
financières ACET
Résultats | 31.12.2015 | 31.12.2016 | 31.12.2017 | 31.12.2018 | 31.12.2019 | 31.12.2020 | 31.12.2021 | 31.12.2022 | 31.12.2023 | 31.12.2024 | Dynamique | |
Revenu Total | 510 179 000 USD | 546 951 000 USD | 558 524 000 USD | 8 181 000 USD | 995 000 USD | 17 903 000 USD | 9 730 000 USD | 24 990 000 USD | - | - | ||
Revenu Opérationnel | 44 272 000 USD | -1 000 USD | -18 882 000 USD | -14 964 000 USD | -31 388 000 USD | -39 191 000 USD | -61 433 000 USD | -72 551 000 USD | -152 038 000 USD | -127 615 000 USD | ||
Revenu Net - (CF) | 29 000 000 USD | -1 000 USD | -33 778 000 USD | -9 299 000 USD | -28 138 000 USD | -36 678 000 USD | -61 999 000 USD | -67 029 000 USD | -142 658 000 USD | -117 122 000 USD | ||
BPA de Base Normalisé | 1.16 USD | - | -1.25 USD | -0.31 USD | -1.88 USD | -5.01 USD | -2.00 USD | -1.63 USD | -3.31 USD | -1.33 USD | ||
Dividende par Action | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | 0.00 USD | ||
Ratio de Distribution | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Total des Actifs | 489 774 000 USD | 540 778 000 USD | 55 193 000 USD | 109 939 000 USD | 81 587 000 USD | 153 835 000 USD | 338 938 000 USD | 330 690 000 USD | 207 295 000 USD | 220 219 000 USD | ||
Total des Passifs | 235 563 000 USD | 236 336 000 USD | 5 502 000 USD | 5 735 000 USD | 141 953 000 USD | 44 008 000 USD | 35 809 000 USD | 38 352 000 USD | 37 120 000 USD | 33 610 000 USD | ||
Ratio d'Endettement | 0.48 | 0.44 | 0.10 | 0.05 | 1.74 | 0.29 | 0.11 | 0.12 | 0.18 | 0.15 | ||
Total des Actifs Courants | 310 310 000 USD | 352 661 000 USD | 54 225 000 USD | 109 534 000 USD | 64 186 000 USD | 94 614 000 USD | 282 438 000 USD | 261 038 000 USD | 162 272 000 USD | 180 136 000 USD | ||
Total des Passifs Courants | 125 000 000 USD | 98 906 000 USD | 5 502 000 USD | 5 716 000 USD | 14 865 000 USD | 13 980 000 USD | 16 317 000 USD | 19 707 000 USD | 19 287 000 USD | 19 392 000 USD | ||
Ratio de Liquidité Courante | 2.48 | 3.57 | 9.86 | 19.16 | 4.32 | 6.77 | 17.31 | 13.25 | 8.41 | 9.29 | ||
Ratio de Liquidité Immédiate | 1.72 | 2.57 | -14.93 | 19.16 | 4.27 | 6.99 | 17.02 | 13.12 | 8.41 | 9.29 | ||
Rendement des Actifs | 5.92 % | - | -61.20 % | -8.46 % | -34.49 % | -23.84 % | -18.29 % | -20.27 % | -68.82 % | -53.18 % | ||
Couverture des Intérêts FFO | 22.27 | -3.00 | -2.70 | - | - | -293.72 | -366.35 | -871.38 | -5 705.32 | -5 705.32 * | ||
Ratio C/B - P/E (LTM) | - | - | - | -27.62 | -0.79 | -2.80 | -8.73 | -5.48 | -0.57 | -0.72 | ||
Rendement du dividende (LTM) | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | ||
Rendement de Rachat (LTM) | - | -12.22 % | 3.82 % | -10.47 % | 49.75 % | 51.11 % | -322.84 % | -32.72 % | -4.78 % | -104.14 % |